Skip to Main Content
Wyss Institute
Menu
Search Site
Who We Are
About
How We Work
How We Collaborate
Team
Careers
Contact
Our Work
Technologies
Impact Report
Business Insider
Publications
Collaborations
Brain Targeting Program
Collaborative Fund Alliance
Diagnostics Accelerator
i3 Center
Northpond Labs Alliance
Newsroom
News
Press Resources
Multimedia
Events
Give
Search
Search results
5 Results for 'Massachusetts General Hospital'
Technologies
(1)
Collaborations
(0)
Team
(0)
News
(3)
Pages
(0)
Multimedia
(1)
Publications
(0)
Jobs
(0)
Events
(0)
Technologies
1
FeCILL: Targeted Treatment for Severe Fungal Infections
FeCILL is novel delivery vehicle for antifungal drugs that targets them right to the infection site and reduces harmful side effects in patients with severe fungal infections.
News
3
Translation News
In a first, genetically edited pig kidney is transplanted into human
March 22, 2024
Press Release
Using the body’s own cells to treat traumatic brain injury
January 3, 2024
Translation News
Wyss Institute’s infant health-promoting technology licensed to Prapela
August 22, 2018
Multimedia
1
Video/Animation
FeCILL: Reimagining How We Treat the Sickest Patients
Opportunistic fungal infections usually only affect patients whose immune systems are compromised, but when they do, they are often deadly – the mortality rate for these infections can be as high as 25%. Existing antifungal treatments have high levels of toxicity, and can harm the patient more than they help. Researchers at the Wyss Institute...
Close search results
close menu
Who We Are
About
How We Work
How We Collaborate
Team
Careers
Contact
Our Work
Technologies
Impact Report
Business Insider
Publications
Collaborations
Brain Targeting Program
Collaborative Fund Alliance
Diagnostics Accelerator
i3 Center
Northpond Labs Alliance
Newsroom
News
Press Resources
Multimedia
Events
Give
Close menu